×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
AMRN – amarin corporation plc - american depositary shares, each representing one ordinary share (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
AMRN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
10/30
04:05 pm
amrn
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
Low
Report
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
10/1
08:00 am
amrn
Amarin Announces Two Upcoming Investor Events
Medium
Report
Amarin Announces Two Upcoming Investor Events
9/19
08:00 am
amrn
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
Low
Report
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer
9/10
07:45 am
amrn
Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer
Low
Report
Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer
9/9
07:30 am
amrn
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe
Low
Report
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe
8/22
08:30 am
amrn
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
Medium
Report
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
Date
Time
Symbol
Company Name
Action
%Chg
10/30/2024
04:05 pm
amrn
amarin corporation plc - american depositary shares, each representing one ordinary share
BEAT
Report
-6.7%
amarin corporation plc - american depositary shares, each representing one ordinary share
7/31/2024
07:00 am
amrn
amarin corporation plc - american depositary shares, each representing one ordinary share
BEAT
Report
-15.4%
amarin corporation plc - american depositary shares, each representing one ordinary share
5/1/2024
07:00 am
amrn
amarin corporation plc - american depositary shares, each representing one ordinary share
BEAT
Report
-6.7%
amarin corporation plc - american depositary shares, each representing one ordinary share
2/29/2024
07:00 am
amrn
amarin corporation plc - american depositary shares, each representing one ordinary share
BEAT
Report
-20.7%
amarin corporation plc - american depositary shares, each representing one ordinary share
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
10/31
04:42 pm
amrn
Form 3 AMARIN CORP PLC\UK For: Oct 23 Filed by: Fishman Peter L.
Low
Report
Form 3 AMARIN CORP PLC\UK For: Oct 23 Filed by: Fishman Peter L.
10/30
04:11 pm
amrn
Form 10-Q AMARIN CORP PLC\UK For: Sep 30
Medium
Report
Form 10-Q AMARIN CORP PLC\UK For: Sep 30
10/30
04:10 pm
amrn
Form 8-K AMARIN CORP PLC\UK For: Oct 30
Low
Report
Form 8-K AMARIN CORP PLC\UK For: Oct 30
10/7
04:15 pm
amrn
Form 8-K AMARIN CORP PLC\UK For: Oct 01
Low
Report
Form 8-K AMARIN CORP PLC\UK For: Oct 01
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/1
Amarin Co. plc (NASDAQ: AMRN) had its price target lowered by analysts at Citigroup Inc from $24.00 to $6.00. They now have a "buy" rating on the stock.
25.4%
7/2 Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance 16.3%
3/13 Amarin Co. plc (NASDAQ: AMRN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 15.2%
4/8 2iQ Global Insider Data Helps Quants Navigate the COVID-19 Crisis 11.9%
11/14 Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial 11.5%
3/2 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Cowen Inc. They set an "outperform" rating and a $23.00 price target on the stock. 10.7%
8/21 Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference 9.9%
10/9 Form 4 AMARIN CORP PLC\UK For: Oct 07 Filed by: Berg Aaron 7.6%
11/12 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. 5.5%
8/9 Form 8-K AMARIN CORP PLC\UK For: Aug 08 4.7%
7/2 Amarin Provides Mid-2019 Update, Including Commercialization Plans for Vascepa® and Updates Full Year 2019 Revenue Guidance 16.3%
3/13 Amarin Co. plc (NASDAQ: AMRN) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 15.2%
4/8 2iQ Global Insider Data Helps Quants Navigate the COVID-19 Crisis 11.9%
11/14 Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsules Label Expansion to Reduce Cardiovascular Risk Based on Landmark REDUCE-IT® Outcomes Trial 11.5%
3/2 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Cowen Inc. They set an "outperform" rating and a $23.00 price target on the stock. 10.7%
8/21 Amarin to Participate in a Fireside Chat at Citi’s 14th Annual Biotech Conference 9.9%
10/9 Form 4 AMARIN CORP PLC\UK For: Oct 07 Filed by: Berg Aaron 7.6%
11/12 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. 5.5%
8/9 Form 8-K AMARIN CORP PLC\UK For: Aug 08 4.7%
TOP News Decliners
3/15
Amarin Takes Proactive Steps to Support Public Health Priorities
-17.6%
12/14 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Leerink Swann. They now have a $29.00 price target on the stock. -14.3%
4/30 Form 10-Q AMARIN CORP PLC\UK For: Mar 31 -13.3%
3/31 Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) -12.3%
8/8 Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA -11.3%
2/26 Form S-3ASR AMARIN CORP PLC\UK -9.6%
3/20 Amarin: Debating The Risk/Reward At These Prices [Seeking Alpha] -9.6%
2/25 Form 10-K AMARIN CORP PLC\UK For: Dec 31 -9.5%
4/2 Form 4 AMARIN CORP PLC\UK For: Mar 31 Filed by: Kennedy Joseph T -8.7%
11/19 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "underperform" rating and a $7.00 price target on the stock. -7.2%
12/14 Amarin Co. plc (NASDAQ: AMRN) had its "buy" rating re-affirmed by analysts at Leerink Swann. They now have a $29.00 price target on the stock. -14.3%
4/30 Form 10-Q AMARIN CORP PLC\UK For: Mar 31 -13.3%
3/31 Amarin Highlights VASCEPA® (Icosapent Ethyl)-Related Data Presented at American College of Cardiology’s Annual Scientific Session Together With World Congress of Cardiology (ACC.20/WCC) -12.3%
8/8 Amarin Announces FDA Notification of Advisory Committee Meeting Planned to be Held in November 2019 in Connection With Vascepa® REDUCE-IT™ sNDA -11.3%
2/26 Form S-3ASR AMARIN CORP PLC\UK -9.6%
3/20 Amarin: Debating The Risk/Reward At These Prices [Seeking Alpha] -9.6%
2/25 Form 10-K AMARIN CORP PLC\UK For: Dec 31 -9.5%
4/2 Form 4 AMARIN CORP PLC\UK For: Mar 31 Filed by: Kennedy Joseph T -8.7%
11/19 Amarin Co. plc (NASDAQ: AMRN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "underperform" rating and a $7.00 price target on the stock. -7.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: